Structured Review

Cell Signaling Technology Inc anti vegf a
Bevacizumab treatment concurrent with nab-paclitaxel chemotherapy is the most effective regimen for inhibiting tumor growth and metastasis. (A, B) Mice bearing 435-LuC + tumors of 450 mm 3 in volume were treated with bevacizumab (4 mg/kg) using three different combination regimens with nab-paclitaxel (10 mg/kg, three cycles of daily for five consecutive days). (A) Schematic illustration of experimental design describing different regimens assessed in this study. Group 1 received three cycles of nab-paclitaxel followed by bevacizumab for the duration of the study, group 2 received bevacizumab concurrent with nab-paclitaxel and both drugs were discontinued at the end of three cycles of nab-paclitaxel, and group 3 received bevacizumab throughout three cycles of nab-paclitaxel and for the duration of the study. (B) Black arrows indicate the start of each cycle of nab-paclitaxel treatment. Data are presented as the mean tumor volume ± SE per group at the indicated days after implantation. Frozen sections from control- (C, top) and nab-paclitaxel-treated (C, bottom) tumors were stained with <t>anti-VEGF-A</t> antibodies and counterstained with 4′,6-diamidino-2-phenylindole to visualize the nuclei. Images were acquired at a constant exposure setting and total fluorescent intensity of VEGF-A staining from control (D, top) and treated (D, bottom) tumor sections was plotted using the ImageJ software as described in the Materials and Methods. Fluorescent intensity plots of representative images in (C) are shown. All images were acquired at a magnification of x200.
Anti Vegf A, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti vegf a/product/Cell Signaling Technology Inc
Average 93 stars, based on 1 article reviews
Price from $9.99 to $1999.99
anti vegf a - by Bioz Stars, 2020-09
93/100 stars

Images

1) Product Images from "Synergy of Nab-paclitaxel and Bevacizumab in Eradicating Large Orthotopic Breast Tumors and Preexisting Metastases 1Synergy of Nab-paclitaxel and Bevacizumab in Eradicating Large Orthotopic Breast Tumors and Preexisting Metastases 1 2"

Article Title: Synergy of Nab-paclitaxel and Bevacizumab in Eradicating Large Orthotopic Breast Tumors and Preexisting Metastases 1Synergy of Nab-paclitaxel and Bevacizumab in Eradicating Large Orthotopic Breast Tumors and Preexisting Metastases 1 2

Journal: Neoplasia (New York, N.Y.)

doi:

Bevacizumab treatment concurrent with nab-paclitaxel chemotherapy is the most effective regimen for inhibiting tumor growth and metastasis. (A, B) Mice bearing 435-LuC + tumors of 450 mm 3 in volume were treated with bevacizumab (4 mg/kg) using three different combination regimens with nab-paclitaxel (10 mg/kg, three cycles of daily for five consecutive days). (A) Schematic illustration of experimental design describing different regimens assessed in this study. Group 1 received three cycles of nab-paclitaxel followed by bevacizumab for the duration of the study, group 2 received bevacizumab concurrent with nab-paclitaxel and both drugs were discontinued at the end of three cycles of nab-paclitaxel, and group 3 received bevacizumab throughout three cycles of nab-paclitaxel and for the duration of the study. (B) Black arrows indicate the start of each cycle of nab-paclitaxel treatment. Data are presented as the mean tumor volume ± SE per group at the indicated days after implantation. Frozen sections from control- (C, top) and nab-paclitaxel-treated (C, bottom) tumors were stained with anti-VEGF-A antibodies and counterstained with 4′,6-diamidino-2-phenylindole to visualize the nuclei. Images were acquired at a constant exposure setting and total fluorescent intensity of VEGF-A staining from control (D, top) and treated (D, bottom) tumor sections was plotted using the ImageJ software as described in the Materials and Methods. Fluorescent intensity plots of representative images in (C) are shown. All images were acquired at a magnification of x200.
Figure Legend Snippet: Bevacizumab treatment concurrent with nab-paclitaxel chemotherapy is the most effective regimen for inhibiting tumor growth and metastasis. (A, B) Mice bearing 435-LuC + tumors of 450 mm 3 in volume were treated with bevacizumab (4 mg/kg) using three different combination regimens with nab-paclitaxel (10 mg/kg, three cycles of daily for five consecutive days). (A) Schematic illustration of experimental design describing different regimens assessed in this study. Group 1 received three cycles of nab-paclitaxel followed by bevacizumab for the duration of the study, group 2 received bevacizumab concurrent with nab-paclitaxel and both drugs were discontinued at the end of three cycles of nab-paclitaxel, and group 3 received bevacizumab throughout three cycles of nab-paclitaxel and for the duration of the study. (B) Black arrows indicate the start of each cycle of nab-paclitaxel treatment. Data are presented as the mean tumor volume ± SE per group at the indicated days after implantation. Frozen sections from control- (C, top) and nab-paclitaxel-treated (C, bottom) tumors were stained with anti-VEGF-A antibodies and counterstained with 4′,6-diamidino-2-phenylindole to visualize the nuclei. Images were acquired at a constant exposure setting and total fluorescent intensity of VEGF-A staining from control (D, top) and treated (D, bottom) tumor sections was plotted using the ImageJ software as described in the Materials and Methods. Fluorescent intensity plots of representative images in (C) are shown. All images were acquired at a magnification of x200.

Techniques Used: Mouse Assay, Staining, Software

2) Product Images from "Metformin inhibits development of diabetic retinopathy through microRNA-497a-5p"

Article Title: Metformin inhibits development of diabetic retinopathy through microRNA-497a-5p

Journal: American Journal of Translational Research

doi:

Metformin attenuates neovascularization in the development of DR through suppressing VEGF-A. (A, B) Vessel density was analyzed at 12 weeks after alloxan, shown by representative images (A), and by quantification (B). (C) ELISA for VEGF-A protein in mouse eyes. (D) RT-qPCR for VEGF-A RNA in mouse eyes. *P
Figure Legend Snippet: Metformin attenuates neovascularization in the development of DR through suppressing VEGF-A. (A, B) Vessel density was analyzed at 12 weeks after alloxan, shown by representative images (A), and by quantification (B). (C) ELISA for VEGF-A protein in mouse eyes. (D) RT-qPCR for VEGF-A RNA in mouse eyes. *P

Techniques Used: Enzyme-linked Immunosorbent Assay, Quantitative RT-PCR

MiR-497a-5p inhibits VEGF-A protein translation in MS1 cells. (A, B) RT-qPCR (A) and Western blot (B) for VEGF-A in miR-497a-5p-modified MS1 cells. *P
Figure Legend Snippet: MiR-497a-5p inhibits VEGF-A protein translation in MS1 cells. (A, B) RT-qPCR (A) and Western blot (B) for VEGF-A in miR-497a-5p-modified MS1 cells. *P

Techniques Used: Quantitative RT-PCR, Western Blot, Modification

MiR-497a-5p targets 3’-UTR of VEGF-A mRNA to inhibit its expression. A: Bioinformatics analyses show that miR-497a-5p targets VEGF-A mRNA. B: Metformin significantly increased the levels of miR-497a-5p in mouse eyes, shown by RT-qPCR. C: We either overexpressed miR-497a-5p, or inhibited miR-497a-5p in MS1 cells by transfection of the cells with a miR-497a-5p-expressing plasmid, or with a plasmid carrying miR-497a-5p antisense (as-miR-497a-5p). The MS1 cells were also transfected with a null plasmid as a control (null). The overexpression or inhibition of miR-497a-5p in NPC cells was confirmed by RT-qPCR. D: MiR-497a-5p-modified MS1 cells were then transfected with 1 μg of VEGF-A-3’-UTR luciferase-reporter plasmid. The luciferase activities were quantified in these cells. *P
Figure Legend Snippet: MiR-497a-5p targets 3’-UTR of VEGF-A mRNA to inhibit its expression. A: Bioinformatics analyses show that miR-497a-5p targets VEGF-A mRNA. B: Metformin significantly increased the levels of miR-497a-5p in mouse eyes, shown by RT-qPCR. C: We either overexpressed miR-497a-5p, or inhibited miR-497a-5p in MS1 cells by transfection of the cells with a miR-497a-5p-expressing plasmid, or with a plasmid carrying miR-497a-5p antisense (as-miR-497a-5p). The MS1 cells were also transfected with a null plasmid as a control (null). The overexpression or inhibition of miR-497a-5p in NPC cells was confirmed by RT-qPCR. D: MiR-497a-5p-modified MS1 cells were then transfected with 1 μg of VEGF-A-3’-UTR luciferase-reporter plasmid. The luciferase activities were quantified in these cells. *P

Techniques Used: Expressing, Quantitative RT-PCR, Transfection, Plasmid Preparation, Over Expression, Inhibition, Modification, Luciferase

Related Articles

Nucleic Acid Electrophoresis:

Article Title: Augmentation of neovascularization in murine hindlimb ischemia by combined therapy with simvastatin and bone marrow-derived mesenchymal stem cells transplantation
Article Snippet: .. Western blot analysis for the expression of VEGF protein in vivo Lysates from hind limb muscle tissue homogenates harvested at day 21 post-surgery were used for Western blot analysis as described previously[ ].Protein was analyzed using 10% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose membranes (Bio-Rad).Membranes were then incubated with primary antibodies including VEGF (1:1000, Cell Signaling) and β-actin (1:5000, Sigma) at 4°C overnight respectively.The membranes were then incubated with peroxidase labeled secondary antibody (1:1000, Santa Cruz, USA) at 37°C for 2 hours. .. Signals were detected by enhanced chemiluminescence (Amersham, USA).

In Vivo:

Article Title: Augmentation of neovascularization in murine hindlimb ischemia by combined therapy with simvastatin and bone marrow-derived mesenchymal stem cells transplantation
Article Snippet: .. Western blot analysis for the expression of VEGF protein in vivo Lysates from hind limb muscle tissue homogenates harvested at day 21 post-surgery were used for Western blot analysis as described previously[ ].Protein was analyzed using 10% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose membranes (Bio-Rad).Membranes were then incubated with primary antibodies including VEGF (1:1000, Cell Signaling) and β-actin (1:5000, Sigma) at 4°C overnight respectively.The membranes were then incubated with peroxidase labeled secondary antibody (1:1000, Santa Cruz, USA) at 37°C for 2 hours. .. Signals were detected by enhanced chemiluminescence (Amersham, USA).

Immunohistochemistry:

Article Title: Overexpression of the Kininogen-1 inhibits proliferation and induces apoptosis of glioma cells
Article Snippet: .. Immunohistochemistry (IHC) Immunohistochemistry was performed with anti-KNG1 (1:200, Abnova), anti-VEGF (1:200, Cell Signaling Technology) and anti-XIAP (1:200, Cell Signaling Technology) antibodies. .. In brief, tissue sections were dewaxed and washed with ethanol (Sigma-Aldrich), followed by incubation with 10% normal goat serum (Vector Laboratories, Burlingame, CA, USA).

Labeling:

Article Title: Augmentation of neovascularization in murine hindlimb ischemia by combined therapy with simvastatin and bone marrow-derived mesenchymal stem cells transplantation
Article Snippet: .. Western blot analysis for the expression of VEGF protein in vivo Lysates from hind limb muscle tissue homogenates harvested at day 21 post-surgery were used for Western blot analysis as described previously[ ].Protein was analyzed using 10% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose membranes (Bio-Rad).Membranes were then incubated with primary antibodies including VEGF (1:1000, Cell Signaling) and β-actin (1:5000, Sigma) at 4°C overnight respectively.The membranes were then incubated with peroxidase labeled secondary antibody (1:1000, Santa Cruz, USA) at 37°C for 2 hours. .. Signals were detected by enhanced chemiluminescence (Amersham, USA).

Incubation:

Article Title: Augmentation of neovascularization in murine hindlimb ischemia by combined therapy with simvastatin and bone marrow-derived mesenchymal stem cells transplantation
Article Snippet: .. Western blot analysis for the expression of VEGF protein in vivo Lysates from hind limb muscle tissue homogenates harvested at day 21 post-surgery were used for Western blot analysis as described previously[ ].Protein was analyzed using 10% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose membranes (Bio-Rad).Membranes were then incubated with primary antibodies including VEGF (1:1000, Cell Signaling) and β-actin (1:5000, Sigma) at 4°C overnight respectively.The membranes were then incubated with peroxidase labeled secondary antibody (1:1000, Santa Cruz, USA) at 37°C for 2 hours. .. Signals were detected by enhanced chemiluminescence (Amersham, USA).

Article Title: Chronic Ethanol consumption modulates growth factor release, mucosal cytokine production and microRNA expression in nonhuman primates
Article Snippet: .. The membranes were incubated in 5% nonfat milk powder diluted in TBST for 30 min at room temperature, and then probed with a human monoclonal anti-STAT3 (1:2000), anti-ARNT antibody (1:1000), anti-HGF (1:5000), anti-VEGF (1:5000) (cell signalling) in 1% milk diluted in 1xTBST overnight at 4°C. .. The membrane was washed three times with 1xTBST and incubated with horseradish peroxidase conjugated secondary antibody (goat antirabbit, 1∶5000) for 2 h at room temperature.

Article Title: Apigenin Protects the Brain against Ischemia/Reperfusion Injury via Caveolin-1/VEGF In Vitro and In Vivo
Article Snippet: .. After being blocked by 5% skim milk in Tris-buffered saline containing TBST, the membranes were incubated with primary antibodies against β -tubulin (Sungene Biotech, China), Caveolin-1 (Santa Cruz Biotechnology, USA), Bcl-2 (Abcam, UK), VEGF (CST, USA), eNOS (Abcam, UK), cleaved Caspase3 (CST, USA), Beclin-1 (CST), and mTOR (CST, USA) and were incubated overnight at 4°C. ..

Article Title: Exogenous morphine inhibits the growth of human gastric tumor in vivo
Article Snippet: .. Following being blocked with 5% bovine serum albumin in Tris-buffered saline/Tween 20 (TBST) for 2 h at room temperature, the membranes underwent incubation at 4 °C overnight using the following primary antibodies: anti-NF-κB (#4764, CST, USA), anti-Bcl-2 (#3498, CST, USA), anti-Bax (#5023, CST, USA), anti-cyclind1 (#2978, CST, USA), anti-VEGF (#2479, CST, USA), and GAPDH (ab181602, Abcam). .. Following incubation with the suitable primary antibodies, the membranes were washed 3 times and incubated for 1.5 h at room temperature using a horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG secondary antibody (ab205718, Abcam).

Expressing:

Article Title: Augmentation of neovascularization in murine hindlimb ischemia by combined therapy with simvastatin and bone marrow-derived mesenchymal stem cells transplantation
Article Snippet: .. Western blot analysis for the expression of VEGF protein in vivo Lysates from hind limb muscle tissue homogenates harvested at day 21 post-surgery were used for Western blot analysis as described previously[ ].Protein was analyzed using 10% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose membranes (Bio-Rad).Membranes were then incubated with primary antibodies including VEGF (1:1000, Cell Signaling) and β-actin (1:5000, Sigma) at 4°C overnight respectively.The membranes were then incubated with peroxidase labeled secondary antibody (1:1000, Santa Cruz, USA) at 37°C for 2 hours. .. Signals were detected by enhanced chemiluminescence (Amersham, USA).

Western Blot:

Article Title: Augmentation of neovascularization in murine hindlimb ischemia by combined therapy with simvastatin and bone marrow-derived mesenchymal stem cells transplantation
Article Snippet: .. Western blot analysis for the expression of VEGF protein in vivo Lysates from hind limb muscle tissue homogenates harvested at day 21 post-surgery were used for Western blot analysis as described previously[ ].Protein was analyzed using 10% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose membranes (Bio-Rad).Membranes were then incubated with primary antibodies including VEGF (1:1000, Cell Signaling) and β-actin (1:5000, Sigma) at 4°C overnight respectively.The membranes were then incubated with peroxidase labeled secondary antibody (1:1000, Santa Cruz, USA) at 37°C for 2 hours. .. Signals were detected by enhanced chemiluminescence (Amersham, USA).

Article Title: Azithromycin effectively inhibits tumor angiogenesis by suppressing vascular endothelial growth factor receptor 2-mediated signaling pathways in lung cancer
Article Snippet: .. Antibodies (dilution, 1:1,000) used in WB analyses included anti-p-VEGFR2 (no. 2478), anti-VEGFR2 (no. 2479), anti-VEGF (no. 2463), anti-hypoxia-inducible factor (HIF; no. 3716), anti-phosphorylated (p)-focal adhesion kinase (FAK; no. 3283), anti-FAK (no. 3285), anti-p-phosphatidylinositol 3-kinase (PI3K; no. 4228), anti-PI3K (no. 4292), anti-p-protein kinase B (Akt; no. 4060), anti-Akt (no. 9272) and anti-actin (no. 4967; all from Cell Signaling Technology, Inc., Danvers, MA, USA). .. Directed in vivo angiogenesis assay The in vivo angiogenesis in Matrigel plug was determined using the directed in vivo angiogenesis assay kit (Trevigen, Inc., Gaithersburg, MD, USA) ( ).

SDS Page:

Article Title: Augmentation of neovascularization in murine hindlimb ischemia by combined therapy with simvastatin and bone marrow-derived mesenchymal stem cells transplantation
Article Snippet: .. Western blot analysis for the expression of VEGF protein in vivo Lysates from hind limb muscle tissue homogenates harvested at day 21 post-surgery were used for Western blot analysis as described previously[ ].Protein was analyzed using 10% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose membranes (Bio-Rad).Membranes were then incubated with primary antibodies including VEGF (1:1000, Cell Signaling) and β-actin (1:5000, Sigma) at 4°C overnight respectively.The membranes were then incubated with peroxidase labeled secondary antibody (1:1000, Santa Cruz, USA) at 37°C for 2 hours. .. Signals were detected by enhanced chemiluminescence (Amersham, USA).

Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 91
    Cell Signaling Technology Inc primary antibodies against vegf
    Effect of scutellarin and scutellarin-loaded nanoparticles on the expression of <t>VEGF,</t> <t>VEGFR2</t> and vWF. a Western blot analysis was used to determine the expression of VEGF,VEGFR2 and vWF in the rat retina. Quantitative evaluation of protein expression of VEGF/GAPDH ( b ), VEGFR2/GAPDH ( c ) and vWF/GAPDH ( d ). Data are presented as mean ± SD. *Significantly different from control group ( P
    Primary Antibodies Against Vegf, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against vegf/product/Cell Signaling Technology Inc
    Average 91 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    primary antibodies against vegf - by Bioz Stars, 2020-09
    91/100 stars
      Buy from Supplier

    93
    Cell Signaling Technology Inc anti vegf a
    Bevacizumab treatment concurrent with nab-paclitaxel chemotherapy is the most effective regimen for inhibiting tumor growth and metastasis. (A, B) Mice bearing 435-LuC + tumors of 450 mm 3 in volume were treated with bevacizumab (4 mg/kg) using three different combination regimens with nab-paclitaxel (10 mg/kg, three cycles of daily for five consecutive days). (A) Schematic illustration of experimental design describing different regimens assessed in this study. Group 1 received three cycles of nab-paclitaxel followed by bevacizumab for the duration of the study, group 2 received bevacizumab concurrent with nab-paclitaxel and both drugs were discontinued at the end of three cycles of nab-paclitaxel, and group 3 received bevacizumab throughout three cycles of nab-paclitaxel and for the duration of the study. (B) Black arrows indicate the start of each cycle of nab-paclitaxel treatment. Data are presented as the mean tumor volume ± SE per group at the indicated days after implantation. Frozen sections from control- (C, top) and nab-paclitaxel-treated (C, bottom) tumors were stained with <t>anti-VEGF-A</t> antibodies and counterstained with 4′,6-diamidino-2-phenylindole to visualize the nuclei. Images were acquired at a constant exposure setting and total fluorescent intensity of VEGF-A staining from control (D, top) and treated (D, bottom) tumor sections was plotted using the ImageJ software as described in the Materials and Methods. Fluorescent intensity plots of representative images in (C) are shown. All images were acquired at a magnification of x200.
    Anti Vegf A, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti vegf a/product/Cell Signaling Technology Inc
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti vegf a - by Bioz Stars, 2020-09
    93/100 stars
      Buy from Supplier

    91
    Cell Signaling Technology Inc rabbit anti vegf
    Effect of curcumin and hypoxia on <t>IGF-1R,</t> p-Akt, p-Erk1/2, HIF-1α, <t>VEGF</t> protein expression in IGF-1R knockout HepG2 cells. (A) IGF-1R, p-Akt, p-Erk1/2, HIF-1α, VEGF protein expression were detected by western blot analysis. Graphic representation of relative density of (B) IGF-1R, (C) p-Akt, (D) p-Erk1/2, (E) HIF-1α and (F) VEGF protein levels, which were normalized to those of β-actin, Akt or Erk1/2, respectively. *P
    Rabbit Anti Vegf, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 91/100, based on 7 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit anti vegf/product/Cell Signaling Technology Inc
    Average 91 stars, based on 7 article reviews
    Price from $9.99 to $1999.99
    rabbit anti vegf - by Bioz Stars, 2020-09
    91/100 stars
      Buy from Supplier

    85
    Cell Signaling Technology Inc rabbit anti vegf receptor 2
    Gene expression analysis of GEnCs cultured on hydrogel substrates at designated time points. (A)  PECAM1  encoding for platelet endothelial cell adhesion molecule or CD31. (B)  CDH5  encoding for cadherin 5 or vascular endothelial cadherin, also known as CD144. (C)  ITGB1  encoding for integrin subunit β1. (D)  ITGB3  encoding for integrin subunit β3. (E)  KDR  encoding for kinase insert domain receptor or vascular endothelial growth factor receptor 2. (F)  TEK  encoding for tyrosine kinase with immunoglobulin-like and EGF-like domains 2 or TIE2. (G)  VWF  encoding for von Willebrand factor. (H)  NOS3  encoding for nitric oxide synthase 3. (I)  PLVAP  encoding for plasmalemma vesicle-associated protein. Values presented as fold-change expression  normalized to gene expression of GEnCs cultured in tissue culture polystyrene on day 0 ( n  = 4).
    Rabbit Anti Vegf Receptor 2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit anti vegf receptor 2/product/Cell Signaling Technology Inc
    Average 85 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rabbit anti vegf receptor 2 - by Bioz Stars, 2020-09
    85/100 stars
      Buy from Supplier

    Image Search Results


    Effect of scutellarin and scutellarin-loaded nanoparticles on the expression of VEGF, VEGFR2 and vWF. a Western blot analysis was used to determine the expression of VEGF,VEGFR2 and vWF in the rat retina. Quantitative evaluation of protein expression of VEGF/GAPDH ( b ), VEGFR2/GAPDH ( c ) and vWF/GAPDH ( d ). Data are presented as mean ± SD. *Significantly different from control group ( P

    Journal: Journal of Nanobiotechnology

    Article Title: Enhancement of scutellarin oral delivery efficacy by vitamin B12-modified amphiphilic chitosan derivatives to treat type II diabetes induced-retinopathy

    doi: 10.1186/s12951-017-0251-z

    Figure Lengend Snippet: Effect of scutellarin and scutellarin-loaded nanoparticles on the expression of VEGF, VEGFR2 and vWF. a Western blot analysis was used to determine the expression of VEGF,VEGFR2 and vWF in the rat retina. Quantitative evaluation of protein expression of VEGF/GAPDH ( b ), VEGFR2/GAPDH ( c ) and vWF/GAPDH ( d ). Data are presented as mean ± SD. *Significantly different from control group ( P

    Article Snippet: Primary antibodies against VEGF, VEGFR2, vWF and Horseradish peroxidase (HRP)-conjugated secondary antibodies were obtained from Cell Signaling Technology (Beverly, MA).

    Techniques: Expressing, Western Blot

    Bevacizumab treatment concurrent with nab-paclitaxel chemotherapy is the most effective regimen for inhibiting tumor growth and metastasis. (A, B) Mice bearing 435-LuC + tumors of 450 mm 3 in volume were treated with bevacizumab (4 mg/kg) using three different combination regimens with nab-paclitaxel (10 mg/kg, three cycles of daily for five consecutive days). (A) Schematic illustration of experimental design describing different regimens assessed in this study. Group 1 received three cycles of nab-paclitaxel followed by bevacizumab for the duration of the study, group 2 received bevacizumab concurrent with nab-paclitaxel and both drugs were discontinued at the end of three cycles of nab-paclitaxel, and group 3 received bevacizumab throughout three cycles of nab-paclitaxel and for the duration of the study. (B) Black arrows indicate the start of each cycle of nab-paclitaxel treatment. Data are presented as the mean tumor volume ± SE per group at the indicated days after implantation. Frozen sections from control- (C, top) and nab-paclitaxel-treated (C, bottom) tumors were stained with anti-VEGF-A antibodies and counterstained with 4′,6-diamidino-2-phenylindole to visualize the nuclei. Images were acquired at a constant exposure setting and total fluorescent intensity of VEGF-A staining from control (D, top) and treated (D, bottom) tumor sections was plotted using the ImageJ software as described in the Materials and Methods. Fluorescent intensity plots of representative images in (C) are shown. All images were acquired at a magnification of x200.

    Journal: Neoplasia (New York, N.Y.)

    Article Title: Synergy of Nab-paclitaxel and Bevacizumab in Eradicating Large Orthotopic Breast Tumors and Preexisting Metastases 1Synergy of Nab-paclitaxel and Bevacizumab in Eradicating Large Orthotopic Breast Tumors and Preexisting Metastases 1 2

    doi:

    Figure Lengend Snippet: Bevacizumab treatment concurrent with nab-paclitaxel chemotherapy is the most effective regimen for inhibiting tumor growth and metastasis. (A, B) Mice bearing 435-LuC + tumors of 450 mm 3 in volume were treated with bevacizumab (4 mg/kg) using three different combination regimens with nab-paclitaxel (10 mg/kg, three cycles of daily for five consecutive days). (A) Schematic illustration of experimental design describing different regimens assessed in this study. Group 1 received three cycles of nab-paclitaxel followed by bevacizumab for the duration of the study, group 2 received bevacizumab concurrent with nab-paclitaxel and both drugs were discontinued at the end of three cycles of nab-paclitaxel, and group 3 received bevacizumab throughout three cycles of nab-paclitaxel and for the duration of the study. (B) Black arrows indicate the start of each cycle of nab-paclitaxel treatment. Data are presented as the mean tumor volume ± SE per group at the indicated days after implantation. Frozen sections from control- (C, top) and nab-paclitaxel-treated (C, bottom) tumors were stained with anti-VEGF-A antibodies and counterstained with 4′,6-diamidino-2-phenylindole to visualize the nuclei. Images were acquired at a constant exposure setting and total fluorescent intensity of VEGF-A staining from control (D, top) and treated (D, bottom) tumor sections was plotted using the ImageJ software as described in the Materials and Methods. Fluorescent intensity plots of representative images in (C) are shown. All images were acquired at a magnification of x200.

    Article Snippet: Primary rabbit anti-Bcl-xL, anti-Akt, anti-p-Akt, anti-p44/42, anti-p-p44/42 anti-p50, anti-p-p50, anti-p65, anti-p p65, anti-VEGF-A, and anti-Bcl-2 antibodies were from Cell Signaling (Danvers, MA) and Thermo Scientific (Waltham, MA).

    Techniques: Mouse Assay, Staining, Software

    Effect of curcumin and hypoxia on IGF-1R, p-Akt, p-Erk1/2, HIF-1α, VEGF protein expression in IGF-1R knockout HepG2 cells. (A) IGF-1R, p-Akt, p-Erk1/2, HIF-1α, VEGF protein expression were detected by western blot analysis. Graphic representation of relative density of (B) IGF-1R, (C) p-Akt, (D) p-Erk1/2, (E) HIF-1α and (F) VEGF protein levels, which were normalized to those of β-actin, Akt or Erk1/2, respectively. *P

    Journal: Experimental and Therapeutic Medicine

    Article Title: Effect of curcumin on vascular endothelial growth factor in hypoxic HepG2 cells via the insulin-like growth factor 1 receptor signaling pathway

    doi: 10.3892/etm.2018.5783

    Figure Lengend Snippet: Effect of curcumin and hypoxia on IGF-1R, p-Akt, p-Erk1/2, HIF-1α, VEGF protein expression in IGF-1R knockout HepG2 cells. (A) IGF-1R, p-Akt, p-Erk1/2, HIF-1α, VEGF protein expression were detected by western blot analysis. Graphic representation of relative density of (B) IGF-1R, (C) p-Akt, (D) p-Erk1/2, (E) HIF-1α and (F) VEGF protein levels, which were normalized to those of β-actin, Akt or Erk1/2, respectively. *P

    Article Snippet: The primary antibodies used in the experiment were as follows: Rabbit anti-IGF-1R (cat. no. 9750), rabbit anti-HIF-1α (cat. no. 3716), rabbit anti-VEGF (cat. no. 2463), rabbit anti-Akt (cat. no. 9272), rabbit anti-phosphorylated (p)-Akt (cat. no. 5012), rabbit anti-extracellular signal-regulated kinases (Erk1/2; cat. no. 4695), rabbit anti-p-Erk1/2 (cat. no. 4377) (all 1:1,000; Cell Signaling Technology, Inc., Danvers, MA, USA) and rabbit anti-β-actin (cat. no. sc-7210; 1:4,000; Santa Cruz Biotechnology, Inc.).

    Techniques: Expressing, Knock-Out, Western Blot

    Molecular mechanisms by which curcumin regulates the IGF-1R signaling pathway and the expression of VEGF in HepG2 cells under CoCl 2 -induced hypoxia. The arrow and blocked arrow (no arrowhead) indicate stimulation and inhibition, respectively. The dotted arrow indicates the translocation of HIF-1α and HIF-1β. The dotted blocked arrow indicates the potential effects of curcumin not directly examined in the present study. It was concluded that curcumin may suppress the expression of HIF-1 and VEGF by targeting IGF-1R or its downstream signaling pathways. VEGF, vascular endothelial growth factor; HIF-1α, hypoxia-inducible factor-1α; HIF-1β, hypoxia-inducible factor-1β; IGF-1, insulin-like growth factor-1; IGF-1R, insulin-like growth factor-1 receptor; PI3K, phosphoinositide-3-kinase; Akt, protein kinase B; MEK, mitogen-activated protein kinase-Erk kinase; Erk, extracellular signal-regulated kinase.

    Journal: Experimental and Therapeutic Medicine

    Article Title: Effect of curcumin on vascular endothelial growth factor in hypoxic HepG2 cells via the insulin-like growth factor 1 receptor signaling pathway

    doi: 10.3892/etm.2018.5783

    Figure Lengend Snippet: Molecular mechanisms by which curcumin regulates the IGF-1R signaling pathway and the expression of VEGF in HepG2 cells under CoCl 2 -induced hypoxia. The arrow and blocked arrow (no arrowhead) indicate stimulation and inhibition, respectively. The dotted arrow indicates the translocation of HIF-1α and HIF-1β. The dotted blocked arrow indicates the potential effects of curcumin not directly examined in the present study. It was concluded that curcumin may suppress the expression of HIF-1 and VEGF by targeting IGF-1R or its downstream signaling pathways. VEGF, vascular endothelial growth factor; HIF-1α, hypoxia-inducible factor-1α; HIF-1β, hypoxia-inducible factor-1β; IGF-1, insulin-like growth factor-1; IGF-1R, insulin-like growth factor-1 receptor; PI3K, phosphoinositide-3-kinase; Akt, protein kinase B; MEK, mitogen-activated protein kinase-Erk kinase; Erk, extracellular signal-regulated kinase.

    Article Snippet: The primary antibodies used in the experiment were as follows: Rabbit anti-IGF-1R (cat. no. 9750), rabbit anti-HIF-1α (cat. no. 3716), rabbit anti-VEGF (cat. no. 2463), rabbit anti-Akt (cat. no. 9272), rabbit anti-phosphorylated (p)-Akt (cat. no. 5012), rabbit anti-extracellular signal-regulated kinases (Erk1/2; cat. no. 4695), rabbit anti-p-Erk1/2 (cat. no. 4377) (all 1:1,000; Cell Signaling Technology, Inc., Danvers, MA, USA) and rabbit anti-β-actin (cat. no. sc-7210; 1:4,000; Santa Cruz Biotechnology, Inc.).

    Techniques: Expressing, Inhibition, Translocation Assay

    Effect of CoCl 2 -induced hypoxia on IGF-1R, HIF-1α and VEGF protein expression in HepG2 cells. (A) Serum-starved IGF-1R knockout HepG2 cells were treated with different concentrations of CoCl 2 (0, 50, 100, 150, 200 and 400 µM) for 6 h. IGF-1R, HIF-1α and VEGF protein expression were detected by western blot analysis. (B) Western blot analysis data was quantified and the protein expression of IGF-1R, HIF-1α and VEGF are presented as a bar graph. *P

    Journal: Experimental and Therapeutic Medicine

    Article Title: Effect of curcumin on vascular endothelial growth factor in hypoxic HepG2 cells via the insulin-like growth factor 1 receptor signaling pathway

    doi: 10.3892/etm.2018.5783

    Figure Lengend Snippet: Effect of CoCl 2 -induced hypoxia on IGF-1R, HIF-1α and VEGF protein expression in HepG2 cells. (A) Serum-starved IGF-1R knockout HepG2 cells were treated with different concentrations of CoCl 2 (0, 50, 100, 150, 200 and 400 µM) for 6 h. IGF-1R, HIF-1α and VEGF protein expression were detected by western blot analysis. (B) Western blot analysis data was quantified and the protein expression of IGF-1R, HIF-1α and VEGF are presented as a bar graph. *P

    Article Snippet: The primary antibodies used in the experiment were as follows: Rabbit anti-IGF-1R (cat. no. 9750), rabbit anti-HIF-1α (cat. no. 3716), rabbit anti-VEGF (cat. no. 2463), rabbit anti-Akt (cat. no. 9272), rabbit anti-phosphorylated (p)-Akt (cat. no. 5012), rabbit anti-extracellular signal-regulated kinases (Erk1/2; cat. no. 4695), rabbit anti-p-Erk1/2 (cat. no. 4377) (all 1:1,000; Cell Signaling Technology, Inc., Danvers, MA, USA) and rabbit anti-β-actin (cat. no. sc-7210; 1:4,000; Santa Cruz Biotechnology, Inc.).

    Techniques: Expressing, Knock-Out, Western Blot

    Gene expression analysis of GEnCs cultured on hydrogel substrates at designated time points. (A)  PECAM1  encoding for platelet endothelial cell adhesion molecule or CD31. (B)  CDH5  encoding for cadherin 5 or vascular endothelial cadherin, also known as CD144. (C)  ITGB1  encoding for integrin subunit β1. (D)  ITGB3  encoding for integrin subunit β3. (E)  KDR  encoding for kinase insert domain receptor or vascular endothelial growth factor receptor 2. (F)  TEK  encoding for tyrosine kinase with immunoglobulin-like and EGF-like domains 2 or TIE2. (G)  VWF  encoding for von Willebrand factor. (H)  NOS3  encoding for nitric oxide synthase 3. (I)  PLVAP  encoding for plasmalemma vesicle-associated protein. Values presented as fold-change expression  normalized to gene expression of GEnCs cultured in tissue culture polystyrene on day 0 ( n  = 4).

    Journal: Biomaterials

    Article Title: Poly(Ethylene Glycol)-Crosslinked Gelatin Hydrogel Substrates with Conjugated Bioactive Peptides Influence Endothelial Cell Behavior

    doi: 10.1016/j.biomaterials.2019.02.001

    Figure Lengend Snippet: Gene expression analysis of GEnCs cultured on hydrogel substrates at designated time points. (A) PECAM1 encoding for platelet endothelial cell adhesion molecule or CD31. (B) CDH5 encoding for cadherin 5 or vascular endothelial cadherin, also known as CD144. (C) ITGB1 encoding for integrin subunit β1. (D) ITGB3 encoding for integrin subunit β3. (E) KDR encoding for kinase insert domain receptor or vascular endothelial growth factor receptor 2. (F) TEK encoding for tyrosine kinase with immunoglobulin-like and EGF-like domains 2 or TIE2. (G) VWF encoding for von Willebrand factor. (H) NOS3 encoding for nitric oxide synthase 3. (I) PLVAP encoding for plasmalemma vesicle-associated protein. Values presented as fold-change expression normalized to gene expression of GEnCs cultured in tissue culture polystyrene on day 0 ( n = 4).

    Article Snippet: Primary antibodies were diluted in Sea Block as follows: mouse anti-PECAM-1 at 1:100 (Abcam, #ab187377) and rabbit anti-VEGF Receptor 2 at 1:200 (Cell Signaling Technology, #2479).

    Techniques: Expressing, Cell Culture

    Gene expression analysis and immunofluorescence staining of HUVECs cultured on hydrogel substrates at designated time points. (A)  PECAM1  encoding for platelet endothelial cell adhesion molecule or CD31. (B)  CDH5  encoding for cadherin 5 or vascular endothelial cadherin, also known as CD144. (C)  ITGB1  encoding for integrin subunit β1. (D)  ITGB3  encoding for integrin subunit β3. (E)  KDR  encoding for kinase insert domain receptor or vascular endothelial growth factor receptor 2. (F)  TEK  encoding for tyrosine kinase with immunoglobulin-like and EGF-like domains 2 or TIE2. (G)  VWF  encoding for von Willebrand factor. (H)  NOS3  encoding for nitric oxide synthase 3. (I)  PLVAP  encoding for plasmalemma vesicle-associated protein. Values presented as fold-change expression normalized to gene expression of HUVECs cultured in tissue culture polystyrene on day 0 ( n  = 4). (J) Whole-mount immunofluorescence staining of HUVECs cultured on hydrogel substrates at 6 and 24 hrs. Merged images: PECAM-1 (green), VEGFR2 (red), and DAPI (blue).

    Journal: Biomaterials

    Article Title: Poly(Ethylene Glycol)-Crosslinked Gelatin Hydrogel Substrates with Conjugated Bioactive Peptides Influence Endothelial Cell Behavior

    doi: 10.1016/j.biomaterials.2019.02.001

    Figure Lengend Snippet: Gene expression analysis and immunofluorescence staining of HUVECs cultured on hydrogel substrates at designated time points. (A) PECAM1 encoding for platelet endothelial cell adhesion molecule or CD31. (B) CDH5 encoding for cadherin 5 or vascular endothelial cadherin, also known as CD144. (C) ITGB1 encoding for integrin subunit β1. (D) ITGB3 encoding for integrin subunit β3. (E) KDR encoding for kinase insert domain receptor or vascular endothelial growth factor receptor 2. (F) TEK encoding for tyrosine kinase with immunoglobulin-like and EGF-like domains 2 or TIE2. (G) VWF encoding for von Willebrand factor. (H) NOS3 encoding for nitric oxide synthase 3. (I) PLVAP encoding for plasmalemma vesicle-associated protein. Values presented as fold-change expression normalized to gene expression of HUVECs cultured in tissue culture polystyrene on day 0 ( n = 4). (J) Whole-mount immunofluorescence staining of HUVECs cultured on hydrogel substrates at 6 and 24 hrs. Merged images: PECAM-1 (green), VEGFR2 (red), and DAPI (blue).

    Article Snippet: Primary antibodies were diluted in Sea Block as follows: mouse anti-PECAM-1 at 1:100 (Abcam, #ab187377) and rabbit anti-VEGF Receptor 2 at 1:200 (Cell Signaling Technology, #2479).

    Techniques: Expressing, Immunofluorescence, Staining, Cell Culture